Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2006 2
2007 6
2008 1
2009 2
2010 2
2011 1
2013 2
2014 5
2015 2
2016 2
2017 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Results by year
Filters applied: . Clear all
Page 1
New genetic loci link adipose and insulin biology to body fat distribution.
Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JMW, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Leach IM, Medina-Gomez C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stančáková A, Sung YJ, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Ärnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Böhringer S, Bonnet F, Böttcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Gräßler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkilä K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Mühleisen TW, Mulas A, Müller G, Müller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Smith AV, Stirrups K, Stringham HM, Sundström J, Swertz MA, Swift AJ, Syvänen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Zhao JH, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman ÅK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT; ADIPOGen Consortium; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GEFOS Consortium; GENIE Consortium; GLGC; ICBP; International Endogene Consortium; LifeLines Cohort Study; MAGIC Investigators; MuTHER Consortium; PAGE Consortium; ReproGen Consortium, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dörr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrières J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliövaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hyppönen E, Illig T, Jarvelin MR, Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Möhlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tönjes A, Tremblay A, Tremoli E, Vohl MC, Völker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jöckel KH, Kivimaki M, Kuh D, Laakso M, Liu Y, März W, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Stefansson K, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Thorsteinsdottir U, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL. Shungin D, et al. Nature. 2015 Feb 12;518(7538):187-196. doi: 10.1038/nature14132. Nature. 2015. PMID: 25673412 Free PMC article.
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.
Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K; Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Petrella T, et al. Cancer Treat Rev. 2007 Aug;33(5):484-96. doi: 10.1016/j.ctrv.2007.04.003. Epub 2007 Jun 11. Cancer Treat Rev. 2007. PMID: 17562357 Review.
CONCLUSION: This systematic review suggests that patients with a good performance status (ECOG 0-1), a normal lactate dehydrogenase level, less than three organs involved or cutaneous and/or subcutaneous metastases, have the highest probability of responding and achieving a durab …
CONCLUSION: This systematic review suggests that patients with a good performance status (ECOG 0-1), a normal lactate dehydrogenase level, l …
I-Tositumomab in lymphoma.
Cheung MC, Maceachern JA, Haynes AE, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Cheung MC, et al. Curr Oncol. 2009 Sep;16(5):32-47. Curr Oncol. 2009. PMID: 19862360 Free PMC article.
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long-term benefi …
Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent …
Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Leuk Lymphoma. 2006 Jun;47(6):967-77. doi: 10.1080/10428190600572582. Leuk Lymphoma. 2006. PMID: 16840185 Review.
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma (NHL) have suggested benefit in patients with relapsed or refractor …
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Init …
High-intensity focused ultrasound for prostate cancer: a systematic review.
Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, Rodrigues G, Shayegan B; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Lukka H, et al. Clin Oncol (R Coll Radiol). 2011 Mar;23(2):117-27. doi: 10.1016/j.clon.2010.09.002. Epub 2010 Oct 6. Clin Oncol (R Coll Radiol). 2011. PMID: 20932728 Review.
High-intensity focused ultrasound (HIFU) has recently been promoted as a non-invasive treatment option for prostate cancer. This systematic review sought to evaluate the evidence comparing it with standard treatment in patients with localised prostate cancer. …
High-intensity focused ultrasound (HIFU) has recently been promoted as a non-invasive treatment option for prostate cancer. This syst …
Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
Berry SR, Cosby R, Asmis T, Chan K, Hammad N, Krzyzanowska MK; Cancer Care Ontario's Gastrointestinal Disease Site Group. Berry SR, et al. Ann Oncol. 2015 Mar;26(3):477-85. doi: 10.1093/annonc/mdu272. Epub 2014 Jul 23. Ann Oncol. 2015. PMID: 25057174 Free article. Review.
BACKGROUND: An important goal of intermittent strategies of delivering systemic treatment as first-line treatment of metastatic colorectal cancer (mCRC) is to maintain efficacy while improving patients' quality of life (QoL). ...
BACKGROUND: An important goal of intermittent strategies of delivering systemic treatment as first-line treatment of metastatic colorectal …
Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario.
Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR; Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Cheung MC, et al. Cancer Treat Rev. 2007 Apr;33(2):161-76. doi: 10.1016/j.ctrv.2006.10.005. Epub 2007 Jan 22. Cancer Treat Rev. 2007. PMID: 17240533 Review.
Rituximab is the first antibody-based therapy approved in cancer. The role of this treatment for non-Hodgkin's lymphoma has evolved significantly since its introduction. ...Validated methodology from the Cancer Care Ontario Program
Rituximab is the first antibody-based therapy approved in cancer. The role of this treatment for non-Hodgkin's lymphoma …
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K; Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care. Hicks LK, et al. Cancer Treat Rev. 2008 Aug;34(5):442-52. doi: 10.1016/j.ctrv.2008.02.003. Epub 2008 Apr 1. Cancer Treat Rev. 2008. PMID: 18381234 Review.
Medline, Embase, Cochrane Controlled Trials Register, and abstracts from the American Society of Hematology and the American Society of Clinical Oncology were searched for randomized controlled trials (RCTs) of either induction or maintenance thalidomide in adults with pre …
Medline, Embase, Cochrane Controlled Trials Register, and abstracts from the American Society of Hematology and the American Society …
Guideline for referral of patients with suspected colorectal cancer by family physicians and other primary care providers.
Del Giudice ME, Vella ET, Hey A, Simunovic M, Harris W, Levitt C. Del Giudice ME, et al. Can Fam Physician. 2014 Aug;60(8):717-23, e383-90. Can Fam Physician. 2014. PMID: 25122815 Free PMC article. Review.
COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Care Ontario Provincial Primary Care and Cancer Network, the members of the Ontario Colorectal Cancer S …
COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Ca
Guideline for referral of patients with suspected lung cancer by family physicians and other primary care providers.
Del Giudice ME, Young SM, Vella ET, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C. Del Giudice ME, et al. Can Fam Physician. 2014 Aug;60(8):711-6, e376-82. Can Fam Physician. 2014. PMID: 25122814 Free PMC article. Review.
COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Care Ontario Provincial Primary Care and Cancer Network and from among the members of the Cancer Care
COMPOSITION OF THE COMMITTEE: Committee members were selected from among the regional primary care leads from the Cancer Ca
26 results